Clinical trial · Interventional
Vitamin C as an Anti-cancer Drug
Evaluation of Cytotoxicity and Genetic Changes of High Dose Vitamin C Infusions in Castration Resistant Metastatic Human Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Can high dose, intravenous Vitamin C prolong life for patients with metastatic prostate cancer? Prostate cancer is the most common cancer (excluding skin cancer) in men in Denmark and the Unites States. When metastatic disease is present cure is no longer possible. The main treatment at this stage is castration, either surgical or medical, ending the patients testosterone production and causing a temporary regression in disease activity. Eventually, the cancer will progress, usually within 2 years from the castration, with a more aggressive course and a survival of 2-3 years. The current treatment option for the patients, who have undergone castration and have disease progression, is chemotherapy with only limited gains in quality of life and survival. This clinical study is a phase 2 study to evaluate the effects of high dose intravenous vitamin c in subjects with early castration resistant prostate cancer. Primary endpoint: * Prostate specific antigen (PSA) changes after 12 to 20 weekly vitamin c infusions Secondary endpoints: * Bone metastases changes after 12 to 20 weekly vitamin c infusions * Changes in bone specific alkaline phosphates, oxidative DNA-damage, PINP, NTX after 12 to 20 weekly vitamin c infusions * RNA-expression changes in prostatic tumor tissue after 12 to 20 weekly vitamin c infusions * RNA-expression changes in lymphocytes after 12 to 20 weekly vitamin c infusions Tertiary endpoints: * Pharmacokinetics of vitamin c in the elderly cancer patients Methods and material: * 80 subjects are included (efficacy evaluation when 20 subjects have been evaluated for extension arm) * Each subject receives a weekly infusion of 60 grams vitamin c (in the form of ascorbate) for 12 to 20 weeks
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ascorbic Acid (Vitamin C) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Vitamin C treatment
- description
- Each subjects receive 12 weeks of 1 weekly treatment with intravenous vitamin c. 5grams are given at week 1, 30 grams at week 2 and 60 grams at week 3-12. If eligibility criteria are met the subject may continue with 1 weekly vitamin c treatment of 60 grams at week 13-20.
- interventionNames
- Drug: Ascorbic Acid (Vitamin C)
Primary outcomes (1)
- measure
- PSA changes after 12-20 weeks of treatment
- timeFrame
- 12, 20 and 26 weeks
Secondary outcomes (5)
- measure
- Bone metastases changes
- timeFrame
- 12, 26 and 52 weeks
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Castration resistant metastatic prostate cancer (bony or visceral metastases) * Gleason sum \> 6 * PSA \> 10 ng/ml * ECOG \< 3 * Prior orchidectomy or LHRH antagonist/agonist treatment * Must give informed content Exclusion Criteria: * Synchronous active cancer (skin cancer excluded) * Prior chemotherapy * History of oxalate renal stones * Glucose-6-phosphate dehydrogenase deficiency * Impaired renal function (creatinine \> 200micromoles/L * Haemochromatosis * Cardiac disease (NYHA \> 2, CSS \> 2, recent AMI (less than 6 months) * Recent major surgery (less than 4 weeks before inclusion and more than 2 days of admittance time) * Prior intended curative treatment of prostate cancer
References
Publications (2)
- DERIVEDNielsen TK, Hojgaard M, Andersen JT, Jorgensen NR, Zerahn B, Kristensen B, Henriksen T, Lykkesfeldt J, Mikines KJ, Poulsen HE. Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a single-arm phase II trial. Transl Androl Urol. 2017 Jun;6(3):517-528. doi: 10.21037/tau.2017.04.42. PMID 28725594
- DERIVEDNielsen TK, Hojgaard M, Andersen JT, Poulsen HE, Lykkesfeldt J, Mikines KJ. Elimination of ascorbic acid after high-dose infusion in prostate cancer patients: a pharmacokinetic evaluation. Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):343-8. doi: 10.1111/bcpt.12323. Epub 2014 Oct 7. PMID 25220574